Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1559)	11/17/2015 1:27:23 PM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

2 year + delay seems to be norm. Look how long we have been waiting for Canadian sales of Vitaros. It was approved in 2010. Partnered in January 2012. Apricus doesn't have a good track record as far as meeting deadlines. Are they too optimistic when they initially set the deadlines? When it comes to RayVa, my thoughts are that they totally underestimated what was needed to complete the RayVa trials. Remember how they only had one site recruiting and that was not going to get the trial done? They had to resort to a CRO, in order to conduct and finish the RayVa Phase 2 A. Now that they have this trial under their belt, they realize that any subsequent trials need to be seasonally programed, and the end result is a 2 Year delay. I myself was not impressed with the 2 year delay. But can I honestly say I am surprised? No.